期刊文献+

可溶性生长刺激表达基因2蛋白在冠心病与心力衰竭的临床应用及研究进展 被引量:5

Clinical application and research progresses of soluble growth stimulation expressed gene 2 protein in coronary artery disease and heart failure
原文传递
导出
摘要 生长刺激表达基因2蛋白(ST2)是白细胞介素1受体/Toll样受体超家族的成员,主要分为可溶性ST2(sST2)和跨模型ST2(ST2L)两种类型,白细胞介素33(IL-33)是其内源性配体。IL-33/ST2L通路具有抗动脉粥样硬化、抗心肌肥厚、抗心肌纤维化等多种心血管保护作用,而sST2作为一种诱骗受体,与IL-33结合则可以阻断上述生物学作用。近来研究发现,sST2作为一种新型生物标志物,在多种心血管疾病的诊治中发挥重要作用。本文将对sST2在冠心病及心力衰竭中的临床研究及进展做一综述。 The growth stimulation expression gene 2 protein(ST2)is a member of the interleukin 1 receptor/Toll-like receptor superfamily with two main types,soluble ST2(sST2)and ligand ST2(ST2L)and interleukin 33(IL-33)is its endogenous ligand.IL-33/ST2L pathway has a variety of cardiovascular protective effects such as anti-atherosclerosis,anti-myocardial hypertrophy and anti-myocardial fibrosis,while sST2,as a decoy receptor,can block these biological effects by binding to IL-33.Recent studies have found that sST2,as a novel biomarker,plays an important role in the diagnosis and treatment of a variety of cardiovascular diseases.Thus,this paper will review the clinical application and research progress of sST2 in coronary heart disease and heart failure.
作者 刘元值 金春子 高立建 赵光贤 Liu Yuanzhi;Jin Chunzi;Gao Lijian;Zhao Guangxian(Department of Cardiology,Yanbian University Hospital,Yanji 133099,China;Coronary Artery Disease Treatment Center,Fuwai Hospital,State Key Laboratory of Cardiovascular Disease,National Center for Cardiovascular Diseases,Beijing 100037,China)
出处 《中华心力衰竭和心肌病杂志(中英文)》 2022年第1期72-76,共5页 Chinese Journal of Heart Failure and Cardiomyopathy
关键词 生长刺激表达基因2蛋白 可溶性 白细胞介素-33 冠状动脉性心脏病 心力衰竭 Growth stimulation expression gene 2 protein,soluble Interleukin 33 Coronary artery disease Heart failure
  • 相关文献

参考文献11

二级参考文献42

  • 1Bauters A, Ennezat PV, Tricot O, et al. Relation of admission white blood cell count to left ventrieular remodeling after anterior wall acute myocardial infarction [ J ]. Am J Cardiol, 2007, 100 (2): 182-184.
  • 2Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise acritical biomechanically induced and cardioprotective signaling system [J]. J Clin Invest, 2007, 117 (6) : 1 538-549.
  • 3Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure [ J ]. J Am Coll Cardiol, 2008, 52 (18) : 1 458-465.
  • 4Weinberg EO, Shimpo M, Hurwitz S, et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker[J]. Circulation, 2003, 207 (5): 721-726.
  • 5Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction[J]. Circulation, 2002, 106 (23): 2 961-966.
  • 6Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease[ J]. Am J Cardiol, 1983, 51 (3): 606.
  • 7Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-I receptor-related protein ST2 and induces T helper type 2-associated eytokines [ J ]. Immunity, 2005, 23 (5) : 479-490.
  • 8Bergers G, Reikerstorfer A, Braselmann S, et al. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins to the IL-1 receptor[J]. EMBO J, 1994, 13 (5): 1 176-188.
  • 9Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction[J]. Circulation, 2004, 109 (18): 2 186-190.
  • 10James L Januzzi, W Frank Peacock, Alan S Maisel, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea [J].J AM Coll Cardiol, 2007, 50 (7): 607-613.

共引文献188

同被引文献60

引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部